Prevalence of JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-7 (e5)
https://doi.org/10.22037/amls.v6.32758
Abstract
Background and Aim: Multiple lines of evidence have been suggested that JAK2 is likely the main candidate gene responsible for the pathogenesis of myeloproliferative neoplasms. The V617F mutation in the pseudokinase domain of JAK2 protein has been detected in a majority of patients. We aimed to evaluate the frequency of this somatic missense substitution among Iranian patients with myeloproliferative neoplasms.
Methods Peripheral blood samples were collected from patients with myeloproliferative neoplasms across different regions of Iran. The JAK2 V617F mutation was identified by allele-specific PCR. To confirm the PCR results, randomly selected positive and negative samples were sequenced.
Results: Among 72 identified patients, 45 (62.5%) were found to harbor JAK2 V617F. The frequencies of the mutation ranged 100% for primary myelofibrosis, 75% for chronic myelogenous leukemia, 67% for polycythemia vera, 62.5% for myelodysplastic/myeloproliferative neoplasms, and 52% for essential thrombocythemia. Our findings revealed that the mutation was more common among men in comparison with women and the correlation between the mutation and gender was statistically significant (p-value<0.01). Additionally, the presence of JAK2 V617F was associated with older ages (p-value =0.009).
Conclusion: The JAK2 V617F mutation was detected in 62.5% of patients with myeloproliferative neoplasms. We have shown that this single acquired point mutation was presented in at least half of the patients. Hence, it seems that the identification of JAK2 V617F mutation in myeloproliferative neoplasms can be very effective in disease diagnosing and management.
*Corresponding Author: Mohammad Hamid; Email: hamidi@pasteur.ac.ir
Please cite this article as: Hamid M, Shahbaz Z. Prevalence of JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms. Arch Med Lab Sci. 2020;6:1-7 (e5). https://doi.org/10.22037/amls.v6.32758
- Myeloproliferative Disorders
- Myeloproliferative Neoplasms
- JAK2 V617F
- Mutation
- Iran
How to Cite
References
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw 2017;15(10):1193-207.
Koschmieder S, Mughal T, Hasselbalch H, Barosi G, Valent P, Kiladjian J, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30(5):1018-24.
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):1-11.
Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi A, Tefferi A.The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood rev. 2016;30(6):453-9.
Holmström MO, Hjortsø M, Ahmad S, Met Ö, Martinenaite E, Riley C, et al. The JAK2 V617F mutation is a target for specific T cells in the JAK2 V617F-positive myeloproliferative neoplasms. Leukemia. 2017;31(2):495-8.
Waldmann TA, Chen J. Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy. Annu Rev Immunol. 2017;35:533-50.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-8.
Guadall A, Lesteven E, Letort G, Toor SA, Delord M, Pognant D, et al. Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features. Thromb Haemost. 2018;118(09):1586-99.
Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007;31(2):233-9.
hao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, et al. Impact of JAK2V617F mutation burden on disease phenotype in Chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci. 2016;13(1):85.
Michiels JJ, Devos T, Schot R, Valster F, Potters V, Schelfout K, et al. Change of the 2008/2016 WHO Criteria into European Clinical, Lab-oratory Molecular and Pathological (ECMP/CLMP) Classification of BRC/ABL Negative Myeloproliferative Neoplasms Caused by JAK2, MPL and CALR Driver Mutations. Hematol Hemother. 2019; 4(1): 1-11.
Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125(4):625-33.
Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. ASH Edu Prog Book. 2005;2005(1):195-200.
Marty C, Lacout C, Droin N, Le Couédic J, Ribrag V, Solary E, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187-95.
Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 V617F mice. Circ Res. 2018;123(11):e35-e47.
Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, et al. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep. 2012;39(9):8663-7.
Silva RRd, Domingues Hatzlhofer BL, Machado CGdF, Lima ASdM, de Albuquerque DM, Santos MNNd, et al. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. Genet Test Mol Biomarkers. 2012;16(7):802-5.
Syeed N. JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies. Asian Pac J Cancer Prev. APJCP 2019;20(12):3611.
McNally R, Li Q, Li K, Dekker C, Vangrevelinghe E, Jones M, et al. Discovery and structural characterization of ATP-site ligands for the wild-type and V617F mutant JAK2 pseudokinase domain. ACS Chem Biol. 2019;14(4):587-93.
Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia. 2008;22(10):1828-40.
Didone A, Nardinelli L, Marchiani M, Ruiz ARL, de Lima Costa AL, Lima IS, et al. Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. Pract Lab Med. 2016;4:30-7.
ZHANG SJ, QIU HX, LI JY, SHI JY, Xu W. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay. Int J Lab Hematol. 2010;32(4):381-6.
Them NC, Kralovics R. Genetic basis of MPN: beyond JAK2-V617F. Curr Hematol Malig Rep. 2013;8(4):299-306.
Zaen-Al-Abideen Pahore TS, Shamsi MT, Tasneem Farzana SH, Nadeem M, Ahmad M, Naz A. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression. J Coll Physicians Surg Pak. 2011;21(8):472-5.
Karimzadeh P, Ghaffari S, Chahardouli B, Zaghal A, Einollahi N, Mousavi S, et al. Evaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-PCR. Iran j pediatr hematol oncol. 2011;2(1):38-42.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365(9464):1054-61.
Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
Wong GC, Kam G, Koay E. JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J. 2011;41(2):191-6.
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41-8.
Chim C, Sim J, Chan C, Kho B, Chan J, Wong L, et al. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients. Hematology. 2010;15(4):187-92.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-68.
Tefferi A. JAK2 mutations in polycythemia vera—molecular mechanisms and clinical applications. N Engl J Med. 2007;356(5):444-5.
Langabeer S, Ainle FN, Conneally E, Lawler M. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci. 2007;176(2):105-9.
Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res. 2010;132(4):423.
Colaizzo D, Amitrano L, Tiscia G, Scenna G, Grandone E, Guardascione M, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5(1):55-61.
Stein BL, Williams DM, Wang N-Y, Rogers O, Isaacs MA, Pemmaraju N, et al. Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090-7.
Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2 V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-307.
Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008;36(11):1480-6. e2.
Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9):1016-21.
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-66.
Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14(1):11-5.
Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, et al. Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018;31(5):690-704.
Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al. Impact of JAK2 (V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther. 2015;9:2687.
- Abstract Viewed: 200 times
- PDF Downloaded: 102 times